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Abstract The matricellular protein CCN2 (connective
tissue growth factor, CTGF) has been previously implicated
in tumorigenesis. In pancreatic cancer cells, CCN2 expres-
sion occurs downstream of ras/MEK/ERK. Direct evidence
that CCN2 mediates tumor progression in pancreatic cancer
has been lacking. An exciting recent report by Bennewith
et al. (Cancer Res 69:775–784, 2009) has used shRNA
knockdown of CCN2 to illustrate that CCN2 contributes to
growth of pancreatic tumor cells, both in vitro and in vivo.
This report briefly summarizes these findings.
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The 5-year survival rate for pancreatic cancer is ~5%
(Jemal et al. 2008). Members of the CCN family, including
CCN2, are dysregulated in cancers and promote angiogen-
esis and metastasis through an integrin-mediated pathway
(Babic et al. 1998; Rachfal et al. 2004; Jiang et al. 2004;
Xie et al., 2004; Shimo et al. 2006; Pickles and Leask
2007). In the case of pancreatic cancer cells, CCN2 was
expressed downstream of ras/ MEK/ERK (Pickles and
Leask 2007). Immunologic inhibition of CCN2 inhibits
the growth and metastasis of xenografted human pancreatic
tumors in mice (Aikawa et al. 2006; Dornhöfer et al. 2006).
However, from these latter studies it was unclear precisely
whether the antibody targeted CCN2 expressed by the tu-
mor cells, derived from the human, or stromal cells, derived
from the mouse. That is, these studies did not explore the
basis of why the anti-CCN2 antibody was impeding tumor
formation and expansion.
Bennewith and colleagues (2009) generated PANC-1
tumor cell lines stably transfected with different shRNA
sequences recognizing CCN2. These tumor lines displayed
impaired growth in soft agar, as well as delayed tumor
growth when pools of shRNA-possessing cells injected
subcutaneously into mice. Intriguingly, the growth kinetics
was delayed owing to clonal selection of tumor cells
displaying high CCN2 expression, indicating that the
stromal microenvironment favored the outgrowth of cells
expressing high CCN2 levels. When clonal populations of
cells were injected into mice, those cells displaying more
efficient knockdown of CCN2 resulted in proportionately
decreased tumor growth and elevated survival. CCN2 is
upregulated in response to hypoxia (Higgins et al. 2004;
Hong et al. 2006), and PANC-1 cells in which CCN2
expression was reduced showed increased susceptibility
to hypoxia-induced apoptosis. The authors reported that
CCN2, significantly, did not affect the growth of PANC-1
cells cultured in normoxia. Finally, CCN2 expression was
found in areas of hypoxia and tumor growth in clinical
pancreatic adenocarcinoma samples.
It was somewhat disappointing that the authors did not
assess, for example, if knockdown of CCN2 affected cell
migration or proliferation, features that CCN2 is known to
promote in other cell types (Blom et al. 2001; Kennedy
et al. 2007; Gao et al. 2004). Moreover, signaling pathways
mediating CCN2 action were not explored. For example, it
may be that while CCN2 expression is downstream of
ras/MEK/ERK (Pickles and Leask 2007) CCN2 may also
promote tumorigenic activities by stimulating this pathway
as well. Indeed, the involvement in CCN2 in acting through
ERK is well-established (Gao et al. 2004; Chen et al. 2004;
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Kennedy et al. 2007). Thus it remains possible that CCN2
may be involved in promoting a loop of constitutive ERK
activation resulting in tumorigenesis.
Nonetheless, the results from Bennewith and colleagues
(2009) strongly support the notion that CCN2 plays a key
role in oncogenesis and that blocking the action of CCN2
may be suitable for precisely targeted drug therapy in cancer.
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